Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 11/20 | 0.46 |
| ▸ | CDC25B | P30305 | 10/20 | 0.46 |
| ▸ | EBP | Q15125 | 3/20 | 0.41 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.38 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450675 | 1.00 | CDC25A (0.46) | CDC25ACDC25BEBPACLYACACA | |
| SCHEMBL1050397 | 0.82 | ACLY (0.48) | CDC25ACDC25BEBPACLYACACA | |
| SCHEMBL300737 | 0.82 | ACLY (0.48) | CDC25ACDC25BEBPACLYACACA | |
| SCHEMBL14116745 | 0.80 | CDC25A (0.51) | CDC25ACDC25BEBPACLYACACA | |
| SCHEMBL2453399 | 0.77 | CDC25A (0.40) | CDC25ACDC25BEBPNPC1L1 | |
| SCHEMBL2453402 | 0.77 | CDC25A (0.40) | CDC25ACDC25BEBPNPC1L1 | |
| SCHEMBL29934951 | 0.75 | CDC25A (0.59) | CDC25ACDC25BEBPACLYACACA | |
| Cycloartanol SCHEMBL1881616 | 0.71 | ACLY (0.67) | CDC25ACDC25BEBPACLYACACA | |
| Cycloartanol SCHEMBL13801860 | 0.71 | ACLY (0.67) | CDC25ACDC25BEBPACLYACACA | |
| Cycloartanol SCHEMBL12152356 | 0.71 | ACLY (0.67) | CDC25ACDC25BEBPACLYACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013036684-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2542085-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | Satori Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011109657-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | CDC25A 3836/4885CDC25B 4224/4885EBP 784/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | CDC25A 4241/4885CDC25B 4330/4885EBP 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.